French, JA;
Perucca, E;
Sander, JW;
Bergfeldt, L;
Baulac, M;
Auerbach, DS;
Keezer, M;
... Welty, TE; + view all
(2021)
FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force.
Epilepsy Currents
10.1177/1535759721996344.
(In press).
Preview |
Text
Sander_FDA Safety Warning on the Cardiac Effects of Lamotrigine- An Advisory From the Ad Hoc ILAE:AES Task Force_AOP.pdf - Published Version Download (531kB) | Preview |
Abstract
The International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Task Force on the cardiac effects of lamotrigine was convened in response to a recent addition to the lamotrigine label by the US Food and Drug Administration (FDA).1 Lamotrigine is the nonproprietary name for a medicine that is sold under its generic name and several brand names including Lamictal™. The present advisory is based on an assessment of currently available evidence. It is not intended to replace regulatory requirements nor is it intended to be an exhaustive review. Its purpose is to advise health care professionals worldwide on how to minimize cardiac safety risks associated with lamotrigine use.
Archive Staff Only
View Item |